Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of octreotide microspheres for prevention of pancreatic fistula after pancreaticoduodenectomy
ChiCTR2400085245Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of octreotide LAR in pancreatic fistula (POPF), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Incidence of clinically relevant postoperative pancreatic fistula at 60 days after surgery. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
octreotide LAR
03
Conditions
pancreatic fistula (POPF)
Beyond the preview
Go deeper on ChiCTR2400085245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085245.